M2 milk platform to develop cell-cultured milk
Building the future of food in the birthplace of cell-cultured milk
Building the future of food in the birthplace of cell-cultured milk
New facility is part of Aptar Pharma’s global expansion program
Express Scripts to add Zepbound to National Preferred Formulary
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Subscribe To Our Newsletter & Stay Updated